{"organizations": [], "uuid": "260e8db03131a6d7022f2e02b8bc1c34c8328f1f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/21/pr-newswire-biotech-market-value-set-to-grow-due-to-technological-advancements.html", "country": "US", "domain_rank": 767, "title": "Biotech Market Value Set to Grow Due to Technological Advancements", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.009, "site_type": "news", "published": "2018-05-21T17:00:00.000+03:00", "replies_count": 0, "uuid": "260e8db03131a6d7022f2e02b8bc1c34c8328f1f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/21/pr-newswire-biotech-market-value-set-to-grow-due-to-technological-advancements.html", "ord_in_thread": 0, "title": "Biotech Market Value Set to Grow Due to Technological Advancements", "locations": [], "entities": {"persons": [], "locations": [{"name": "new york", "sentiment": "none"}], "organizations": [{"name": "global market insights, inc.", "sentiment": "neutral"}, {"name": "avalon globocare corp.", "sentiment": "none"}, {"name": "atara biotherapeutics, inc.", "sentiment": "none"}, {"name": "athersys, inc.", "sentiment": "none"}, {"name": "sangamo therapeutics, inc.", "sentiment": "none"}, {"name": "atra", "sentiment": "none"}, {"name": "avco", "sentiment": "none"}, {"name": "vericel corporation", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, May 21, 2018 /PRNewswire/ --\nAccording to a report by Global Market Insights, Inc., the Biotechnology Market size is projected to reach USD 775.2 billion with 9.9% CAGR by 2024. Based on technology, the industry is segmented into tissue engineering and regeneration, fermentation, PCR, nanobiotechnology, chromatography, DNA sequencing, and more. In recent years, the tissue engineering and regeneration segments have went through rapid growth, and accounted for highest revenue, valued at over USD 104.5 billion. Other segments such as the nanobiotechnology, fermentation and cell-based assay segments will experience strong growth thanks to rising R&D investments by various biotechnological and pharmaceutical companies. Avalon GloboCare Corp. (OTC: AVCO), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Athersys, Inc. (NASDAQ: ATHX), Atara Biotherapeutics, Inc. (NASDAQ: ATRA), Vericel Corporation (NASDAQ: VCEL)\nThe regenerative medicine segment has emerged with promising approaches to treat complicated degenerative disorders in recent years. According to Markets and Markets the global Regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6% from 2016 to 2021. Emerging technological advances in cell-based and gene therapies are major factors contributing to the industry's development.\nAvalon GloboCare Corp. (OTCQB: AVCO) last week announced breaking news that, \"financial results and provided a business update for the first quarter ended March 31, 2018.\nFirst Quarter 2018 Highlights:\nRevenues increased 365% to $307,913 for the first quarter ended March 31, 2018; Cash at March 31, 2018 was $2.1 million; Teamed up with Weill Cornell Medicine to establish joint translational research initiative in stem cell technology and regenerative medicine; Formed strategic partnership with major biomedical enterprise Da An Gene Co., Ltd. (\"Da An Gene\"); Majority-owned subsidiary, GenExosome Technologies Inc., launched its U.S. operations in Ohio; Formed joint laboratory with top-ranked hospital in Shanghai for regenerative exosomics; Submitted application for Nasdaq listing.\nDavid Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp., stated, \"We made significant progress in the first quarter of 2018. We started off the year by forming a strategic partnership with Da An Gene, which is a leader in the molecular diagnostics market. We believe this partnership will help significantly accelerate our product development and commercialization by leveraging Da An Gene's genomic sequencing and profiling platform, as well as its commercial network.\"\n\"We have continued our expansion in the U.S. by launching operations of our GenExosome subsidiary in Ohio, where we plan to market and distribute our Exosome Isolation Systems. We are making progress with our commercial launch and believe this technology has the potential to transform the liquid biopsy and regenerative medicine markets by making exosome-specific diagnostics and therapies readily available and commercially viable. Continuing our U.S. growth, we have also jointly established a translational research training program with the Shahin Rafii Laboratory of the Division of Regenerative Medicine at Weill Cornell Medicine in New York. The joint laboratory provides us access to a world-class stem cell facility along with the existing clinical resources available to us through the Lu Daopei hospital network,\" continued Dr. Jin.\n\"Importantly, we are moving forward with our plans to list on NASDAQ, which we believe will provide us greater exposure within the investment community as we execute on our upcoming milestones,\" concluded Dr. Jin.\nRevenues for the first quarter ended March 31, 2018 were $307,913 versus $66,286 for the first quarter ended March 31, 2017. The increase in revenues was due to property rental income, development services and sales of developed products. Operating loss for the quarter ended March 31, 2018 was $1.3 million versus operating loss of $0.5 million for first quarter ended March 31, 2017, which reflects increased SG&A expenses to support the anticipated growth, as well as an increase in public company expenses in advance of the planned listing on a national exchange. Net loss for the first quarter ended March 31, 2018 was $1.55 million or ($0.02) earnings per share, versus net loss of $0.55 million or ($0.01) earnings per share for the first quarter ended March 31, 2017.\"\nSangamo Therapeutics, Inc. (NASDAQ: SGMO) is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo has exclusive, global collaboration and license agreements with Kite, a Gilead Company, to develop next-generation autologous and allogeneic engineered cell therapies for the treatment of cancer using zinc finger nuclease genome editing technology; with Pfizer Inc. for gene therapy programs for Hemophilia A; with Bioverativ, a Sanofi Company, for hemoglobinopathies, including beta-thalassemia and sickle cell disease. On April 27, 2018, the company announced that the California Institute for Regenerative Medicine (CIRM) has awarded an $8 million grant for Sangamo to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.\nAthersys, Inc. (NASDAQ: ATHX) is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived \"off-the-shelf\" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Earlier this month, the company announced its financial results for the three months ended March 31, 2018. The company said Revenues decreased to $1.1 million for the three months ended March 31, 2018 compared to $1.5 million for the three months ended March 31, 2017. Progressed Phase 1/2 study evaluated MultiStem therapy in acute respiratory distress syndrome (ARDS) patients.\nAtara Biotherapeutics, Inc. (NASDAQ: ATRA) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Earlier this month, the company announced that it has expanded its collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop the next generation of genetically engineered chimeric antigen receptor T-cell (CAR T) immunotherapies. This agreement is the next step in Atara's strategy to leverage the potential of the Company's technology platform to develop genetically modified off-the-shelf, allogeneic T-cell immunotherapies to transform the lives of patients with serious medical conditions. Under the agreement, Atara will gain access to several of MSK's innovative enabling technologies, including a novel CAR T construct that Atara believes has physiologic T-cell activation properties, as well as methods for designing CAR T immunotherapies.\nVericel Corporation (NASDAQ: VCEL) is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. On May 8, 2018, the company reported financial results and business highlights for the first quarter ended March 31, 2018. Total net revenues of $18.0 million compared to $9.4 million in the first quarter of 2017; first quarter 2017 revenues included a $2.8 million revenue reserve for Carticel® and MACI® related to a contractual dispute between one of the Company's pharmacy providers and a third-party payer.\nSubscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia\nFollow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz\nFollow and talk to us on Instagram: https://www.instagram.com/financialbuzz\nFacebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz\nAbout FinancialBuzz.com\nFinancialBuzz.com , a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.\nPlease Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com , a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For avalon globocare corp. financial news dissemination and PR services, FinancialBuzz.com expects to be compensated three thousand dollars by chineseinvestors inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com , members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com . By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com . Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .\nFor further information:\nMedia Contact: info@financialbuzz.com\n+1-877-601-1879\nUrl: http://www.FinancialBuzz.com\nSOURCE FinancialBuzz.com", "external_links": ["https://www.facebook.com/Financialbuzz", "https://www.instagram.com/financialbuzz", "https://www.youtube.com/FinancialBuzzMedia", "https://twitter.com/financialbuzz"], "published": "2018-05-21T17:00:00.000+03:00", "crawled": "2018-05-21T18:40:17.014+03:00", "highlightTitle": ""}